Interview David Segarra – CEO and Co-Founder of aptaTargets

by GENESIS Biomed

David Segarra: “ApToll is an immune modulator to treat ischaemic stroke in the acute phase. We have successfully completed Phase 2a and will soon conduct Phase 2b. We are also testing ApToll for oth...

Read more

‘JAMA Neurology’ publishes the results from Phase 1b/2a clinical trial of the neuroprotective drug ApTOLL for ischemic stroke

by AptaTargets

The results from APRIL study, previously presented at the International Stroke Conference 2023, indicate that ApTOLL showed good safety in 151 acute ischemic stroke patients.

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

New breakthrough in developing more pers...

by Universitat de Barcelona

The results show that adenocarcinoma exhibits much more active and fun...

Photos Stream